

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM838980

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Titan Pharmaceuticals, Inc.		09/01/2023	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Fedson, Inc.		
<b>Street Address:</b>	1180 Seminole Trail		
<b>City:</b>	Charlottesville		
<b>State/Country:</b>	VIRGINIA		
<b>Postal Code:</b>	22901		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 2</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	4102980	PROBUPHINE	
<b>Registration Number:</b>	5492404	PRONEURA	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2037822889		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	203.498.4347		
<b>Email:</b>	fduffin@wiggin.com		
<b>Correspondent Name:</b>	Francis J. Duffin, Wiggin and Dana LLP		
<b>Address Line 1:</b>	One Century Tower, 265 Church Street		
<b>Address Line 4:</b>	New Haven, CONNECTICUT 06510		
<b>NAME OF SUBMITTER:</b>	Francis J. Duffin		
<b>SIGNATURE:</b>	/fjd/		
<b>DATE SIGNED:</b>	09/13/2023		
<b>Total Attachments: 29</b>			
source=Titan to Fedson#page1.tif			
source=Titan to Fedson#page2.tif			
source=Titan to Fedson#page3.tif			
source=Titan to Fedson#page4.tif			
source=Titan to Fedson#page5.tif			

CH \$65.00 4102980

source=Titan to Fedson#page6.tif  
source=Titan to Fedson#page7.tif  
source=Titan to Fedson#page8.tif  
source=Titan to Fedson#page9.tif  
source=Titan to Fedson#page10.tif  
source=Titan to Fedson#page11.tif  
source=Titan to Fedson#page12.tif  
source=Titan to Fedson#page13.tif  
source=Titan to Fedson#page14.tif  
source=Titan to Fedson#page15.tif  
source=Titan to Fedson#page16.tif  
source=Titan to Fedson#page17.tif  
source=Titan to Fedson#page18.tif  
source=Titan to Fedson#page19.tif  
source=Titan to Fedson#page20.tif  
source=Titan to Fedson#page21.tif  
source=Titan to Fedson#page22.tif  
source=Titan to Fedson#page23.tif  
source=Titan to Fedson#page24.tif  
source=Titan to Fedson#page25.tif  
source=Titan to Fedson#page26.tif  
source=Titan to Fedson#page27.tif  
source=Titan to Fedson#page28.tif  
source=Titan to Fedson#page29.tif

## INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

This Intellectual Property Assignment Agreement (“IP Assignment”) is made, entered into, and effective as of September 1, 2023, by and between **Fedson, Inc.**, a Delaware corporation (“Assignee”), and **Titan Pharmaceuticals, Inc.**, a Delaware corporation (“Assignor”). All capitalized terms used in this Agreement without definition have the meanings given to them in the Purchase Agreement (as defined below).

WHEREAS, Assignor and Assignee are parties to that certain Asset Purchase Agreement, dated as of July 26, 2023 (“Purchase Agreement”), pursuant to which Assignor has conveyed, transferred and assigned to Assignee, among other assets, certain intellectual property of Assignor, and have agreed to execute and deliver this IP Assignment, for recording with the United States Patent and Trademark Office and corresponding entities or agencies in any applicable jurisdictions;

NOW THEREFORE, Assignor agree as follows:

1. Assignment. For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby irrevocably conveys, transfers and assigns to Assignee, and Assignee hereby accepts, all of Assignor’s right, title and interest in and to the following (the “Assigned IP”):

(a) the patent registrations and applications set forth on Schedule 1 hereto and all issuances, divisions, continuations, continuations-in-part, reissues, extensions, reexaminations and renewals thereof (the “Patents”);

(b) the trademark registrations and applications set forth on Schedule 2 hereto and all issuances, extensions and renewals thereof (the “Trademarks”), together with the goodwill of the business connected with the use of, and symbolized by, the Trademarks;

(c) all rights of any kind whatsoever of Assignor accruing under any of the foregoing provided by applicable law of any jurisdiction, by international treaties and conventions, and otherwise throughout the world;

(d) any and all royalties, fees, income, payments and other proceeds now or hereafter due or payable with respect to any and all of the foregoing; and

(e) any and all claims and causes of action with respect to any of the foregoing, whether accruing before, on, or after the date hereof, including all rights to and claims for damages, restitution, and injunctive and other legal and equitable relief for past, present, and future infringement, dilution, misappropriation, violation, misuse, breach or default, with the right but no obligation to sue for such legal and equitable relief and to collect, or otherwise recover, any such damages.

2. Recordation and Further Actions. Assignor hereby authorize the Commissioner for Trademarks in the United States Patent and Trademark Office and the officials of corresponding entities or agencies in any applicable jurisdictions to record and register this IP Assignment upon request by Assignee. Following the date hereof, upon Assignee’s reasonable request, Assignor shall take such steps and actions, and provide such cooperation and assistance to Assignee and Assignee’s successors, assigns and legal representatives, including the execution and delivery of any affidavits, declarations, oaths, exhibits, assignments, powers of attorney or other documents, as may be reasonably necessary to effect, evidence or perfect the assignment of the Assigned IP to Assignee, or any assignee or successor thereto.

3. Terms of the Asset Purchase Agreement. This IP Assignment shall be subject to the provisions set forth in Article IX (General) of the Purchase Agreement, and such provisions are incorporated herein by this reference, mutatis mutandis. In the event of any conflict or inconsistency between the terms of the Purchase Agreement and the terms hereof, the terms of the Purchase Agreement shall govern.

*(SIGNATURE PAGES FOLLOW)*

The parties hereto have executed this Intellectual Property Assignment Agreement effective as of the date first written above.

**ASSIGNEE:**

FEDSON, INC.

**ASSIGNOR:**

TITAN PHARMACEUTICALS, INC.

DocuSigned by:  
*Alan Garvin*  
By: \_\_\_\_\_  
270617D0C47F44B...

Name: Alan Garvin

Title: President

By: *David Lazar* \_\_\_\_\_

Name: David Lazar

Title: CEO

## SCHEDULE 1

## ASSIGNED PATENT REGISTRATIONS AND PATENT APPLICATIONS

<u>MoFo Docket # Client Ref #</u>	<u>Country</u>	<u>Title</u>	<u>App # Filing Date</u>	<u>Patent # Grant Date</u>	<u>Parent # Filing Date</u>	<u>Category</u>	<u>Inventor (s)</u>	<u>Owner</u>	<u>Status</u>
30414-20008.00	US United States	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE	10/453,377 06-02-2003	7,736,665 06-15-2010	60/384,733 05-31-2002	Non-provisional IUS application	Rajesh A. Patel Louis R. Bucalo	Titan Pharmaceutical, Inc.	Grant
30414-20008.31	US United States	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE	17/472,502 09-10-2021		16/820,574 03-16-2020	Continuation	Rajesh A. Patel Louis R. Bucalo	Titan Pharmaceutical, Inc.	Filed
30414-20008.42	CA Canadian	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE	2487577 06-02-2003	2487577 11-18-2014	PCT/US03/17401 06-02-2003	PCT National Phase	Rajesh A. Patel Louis R. Bucalo	Titan Pharmaceutical, Inc.	Grant

		NE							
30414-20009, 02	US United States	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	13/525,193 06-15-2012	8,852,623 10-07-2014	12/119,334 05-12-2008	Continuation	Rajesh A. Patel Louis R. Bucalo Lauren Costanti Sofie Kleppner	Titan Pharmaceuticals, Inc.	Granted
30414-20009, 03	US United States	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST	14/506,426 10-03-2014	9,278,163 03-08-2016	13/525,193 06-15-2012	Continuation	Rajesh A. Patel Louis R. Bucalo Lauren Costanti Sofie Kleppner	Titan Pharmaceuticals, Inc.	Granted
30414-20045, 00	US United States	HETEROGENEOUS IMPLANTABLE DRUG DELIVERY DEVICES FOR	13/634,535 03-16-2011	10,111,830 10-30-2018	PCT/US2011/028 727 03-16-2011	PCT National Phase	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutical, Inc.	Granted

30414-20045.01	US United States	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	13/802,504 03-16-2011	10,123,971 11-13-2018	13/634,535 03-16-2011	Continuation	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceuticals, Inc.	Granted
30414-20045.41	AU Australian	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	2011227289 03-16-2011	2011227289 05-05-2016	PCT/US2011/028 727 03-16-2011	PCT National Phase	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceuticals, Inc.	Granted
30414-20045.42	CA Canadian	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	2792179 03-16-2011	2,792,179 04-02-2019	PCT/US2011/028 727 03-16-2011	PCT National Phase	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceuticals, Inc.	Granted
30414-20045.44	HK Hong Kong	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	131086402 03-16-2011	1181311 B 08-30-2019	11756957.4 03-16-2011	Re-registration of European Patent	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceuticals, Inc.	Granted
30414-20045.45	IN Indian	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG	8733/DELNP/20 12 03-16-2011	313830 06-07-2019	PCT/US2011/028 727 03-16-2011	PCT National Phase	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceuticals, Inc.	Granted



		DELIVERY											
30414-20045.	JP Japanese	HETEROGENEO US	2013500190 03-16-2011	5869551 01-15-2016	PCT/ US2011/ 028 727 03-16-2011	PCT National Phase	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed				
30414-20045.	KR South Korean	HETEROGENEO US	1020127026810 03-16-2011	10-1914119 10-26-2018	PCT/ US2011/ 028 727 03-16-2011	PCT National Phase	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed				
30414-20045.	MX Mexican	HETEROGENEO US	MX/a/2012/010 611 03-16-2011	354444 03-06-2018	PCT/ US2011/ 028 727 03-16-2011	PCT National Phase	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed				
30414-20045.	SG Singapore	HETEROGENEO US	2012067989 03-16-2011	184059 04-16-2015	PCT/ US2011/ 028 727 03-16-2011	PCT National Phase	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed				

30414-20045.	ZA South African	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	201206563 03-16-2011	2012/06563 12-20-2017	PCT/US2011/028 727 03-16-2011	PCT National Phase	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed
30414-20045.	SG Singapore	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	10201501964Q 03-16-2011	10201501964Q 11-07-2018	2012067989 03-16-2011	Divisional	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed
30414-20045.	JP Japanese	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	2015159516 03-16-2011	6022649 10-14-2016	2013500190 03-16-2011	Divisional	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed
30414-20045.	AL Albanian	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	AL/P/2018/825 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed
30414-20045.	AT Austrian	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG	11756957.4 03-16-2011	1034308 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed

			DELIVERY																
30414-20045.55	BE Belgian	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	2547332 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed										
30414-20045.56	BG Bulgarian	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	2547332 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed										
30414-20045.57	CH Swiss	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	2547332 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed										
30414-20045.58	CY Cyprian	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	CY2018110127 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed										

30414-20045.	CZ	Czech Republic	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4	2011-756957	03-16-2011	11756957.4	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed
30414-20045.	DE	German	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4	60 2011 051 530.6	03-16-2011	11756957.4	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed
30414-20045.	DK	Danish	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4	2547332	03-16-2011	11756957.4	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed
30414-20045.	EE	Estonian	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4	E016534	03-16-2011	11756957.4	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed
30414-20045.	ES	Spanish	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG	11756957.4	ES2699200	03-16-2011	11756957.4	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed

		DELIVERY																		
30414-20045.	FI Finnish	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	2547332 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed											
30414-20045.	FR French	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	2547332 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed											
30414-20045.	GB British	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	2547332 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed											
30414-20045.	GR Greek	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	3098147 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed											

30414-20045.	HR Croatian	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	P20182014 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed
30414-20045.	HU Hungaria n	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	E041040 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed
30414-20045.	IE Irish	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	2547332 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed
30414-20045.	IS Icelandic	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	2547332 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed
30414-20045.	IT Italian	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	502018000036 432 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed

		DELIVERY																	
30414-20045.73	LT Lithuania n	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	2547332 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed										
30414-20045.74	LU Luxembo urg	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	2547332 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed										
30414-20045.75	LV Latvian	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	2547332 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed										
30414-20045.76	MC Monaco	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	2547332 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed										

30414-20045.	MK Macedoni a (F.Y.R.O. M.)	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	MK/P/2018/95 6 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed
30414-20045. 78	MT Maltese	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	PT36857 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed
30414-20045. 79	NL Dutch	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	2547332 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed
30414-20045. 80	NO Norwegia n	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	2547332 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed
30414-20045. 81	PL Polish	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG	11756957.4 03-16-2011	2547332 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed



		DELIVERY																	
30414-20045.	PT Portugues e	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	201810000709 55 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed										
30414-20045.	RO Romanian	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	EP/02625 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed										
30414-20045.	RS Serbia	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	RS-P-2018- 1407 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed										
30414-20045. 85	SE Swedish	HETEROGENEO US IMPLANTABLE DEVICES FOR DRUG DELIVERY	11756957.4 03-16-2011	2547332 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed										

30414-20045.	SI Slovenian	HETEROGENEO US	11756957.4 03-16-2011	201131621 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed
30414-20045.	SK Slovak Republic	HETEROGENEO US	11756957.4 03-16-2011	E 29220 T3 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed
30414-20045.	SM San Marino	HETEROGENEO US	11756957.4 03-16-2011	SM-T- 201800629 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed
30414-20045.	TR Turkish	HETEROGENEO US	11756957.4 03-16-2011	2018/17364 08-29-2018	11756957.4 03-16-2011	EP National Stage	Rajesh A. Patel Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Grant ed
30414-20046. 00	US United States	IMPLANTABLE DEVICES FOR DRUG DELIVERY WITH	16/338,962 10-05-2017		PCT/US2017/055 432 10-05-2017	PCT National Phase	Rajesh A. Patel Sunil Sreedhar an	Titan Pharmaceutic als, Inc.	Filed

		REDUCED BURST RELEASE					Sunil R. Bhonsle		
30414-20046.01	US United States	IMPLANTABLE DEVICES FOR DRUG DELIVERY WITH REDUCED BURST RELEASE (MOFO NOT RESPONSIBLE - FOR MONITORING PURPOSES ONLY)	18/076,023 12-06-2022	16/338,962 10-05-2017	Continuation	Rajesh A. Patel Sunil Sreedharan Sunil R. Bhonsle	Titan Pharmaceuticals, Inc.	Filed	
30414-20046.41	AU Australian	IMPLANTABLE DEVICES FOR DRUG DELIVERY WITH REDUCED BURST RELEASE	2017338924 10-05-2017	PCT/US2017/055 432 10-05-2017	PCT National Phase	Rajesh A. Patel Sunil Sreedharan Sunil R. Bhonsle	Titan Pharmaceuticals, Inc.	Filed	
30414-20046.42	CA Canadian	IMPLANTABLE DEVICES FOR DRUG DELIVERY	3,039,051 10-05-2017	PCT/US2017/055 432 10-05-2017	PCT National Phase	Rajesh A. Patel Sunil Sreedhar	Titan Pharmaceuticals, Inc.	Filed	

		WITH REDUCED BURST RELEASE				an Sunil R. Bhonsle		
30414- 20046. 43	CN Chinese	IMPLANTABLE DEVICES FOR DRUG DELIVERY WITH REDUCED BURST RELEASE	201780074743. 5 10-05-2017	PCT/US2017/055 432 10-05-2017	PCT National Phase	Rajesh A. Patel Sunil Sreedhar an Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Filed
30414- 20046. 44	EP European	IMPLANTABLE DEVICES FOR DRUG DELIVERY WITH REDUCED BURST RELEASE	17859227.5 10-05-2017	PCT/US2017/055 432 10-05-2017	PCT National Phase	Rajesh A. Patel Sunil Sreedhar an Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Filed
30414- 20046. 45	IN Indian	IMPLANTABLE DEVICES FOR DRUG DELIVERY WITH REDUCED BURST RELEASE	201917016487 10-05-2017	PCT/US2017/055 432 10-05-2017	PCT National Phase	Rajesh A. Patel Sunil Sreedhar an Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Filed

30414-20046.46	JP Japanese	IMPLANTABLE DEVICES FOR DRUG DELIVERY WITH REDUCED BURST RELEASE	2019-518024 10-05-2017		PCT/US2017/055 432 10-05-2017	PCT National Phase	Rajesh A. Patel Sunil Sreedhar an Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Filed
30414-20046.47	KR South Korean	IMPLANTABLE DEVICES FOR DRUG DELIVERY WITH REDUCED BURST RELEASE	10-2019-7011844 10-05-2017		PCT/US2017/055 432 10-05-2017	PCT National Phase	Rajesh A. Patel Sunil Sreedhar an Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Filed
30414-20046.48	MX Mexican	IMPLANTABLE DEVICES FOR DRUG DELIVERY WITH REDUCED BURST RELEASE	MX/a/2019/003 804 10-05-2017		PCT/US2017/055 432 10-05-2017	PCT National Phase	Rajesh A. Patel Sunil Sreedhar an Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Filed
30414-20046.49	SG Singapore	IMPLANTABLE DEVICES FOR DRUG DELIVERY WITH REDUCED	11201902851R 10-05-2017		PCT/US2017/055 432 10-05-2017	PCT National Phase	Rajesh A. Patel Sunil Sreedhar an Sunil R.	Titan Pharmaceutic als, Inc.	Filed

		BURST RELEASE					Bhonsle		
30414-20046.50	ZA South African	IMPLANTABLE DEVICES FOR DRUG DELIVERY WITH REDUCED BURST RELEASE	2019/02259 10-05-2017		PCT/US2017/055 432 10-05-2017	PCT National Phase	Rajesh A. Patel Sunil Sreedhar an Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Filed
30414-20046.51	HK Hong Kong	IMPLANTABLE DEVICES FOR DRUG DELIVERY WITH REDUCED BURST RELEASE	19129475.0 10-05-2017		17859227.5 10-05-2017	Re- registratio n of European Patent Applicatio n	Rajesh A. Patel Sunil Sreedhar an Sunil R. Bhonsle	Titan Pharmaceutic als, Inc.	Filed
30414-20047.00	US United States	LOADABLE POROUS STRUCTURES FOR USE AS IMPLANTS	17/253,077 06-25-2019		PCT/US2019/039 070 06-25-2019	PCT National Phase	Rajesh A. Patel	Titan Pharmaceutic als, Inc.	Filed
30414-20047.41	AU Australian	LOADABLE POROUS STRUCTURES FOR USE AS	2019294614 06-25-2019		PCT/US2019/039 070 06-25-2019	PCT National Phase	Rajesh A. Patel	Titan Pharmaceutic als, Inc.	Filed

		IMPLANTS							
30414-20047.	CN Chinese	LOADABLE POROUS STRUCTURES FOR USE AS IMPLANTS	201980055367. 4		PCT/US2019/039 070 06-25-2019	PCT National Phase	Rajesh A. Patel	Titan Pharmaceutic als, Inc.	Filed
30414-20047.	CA Canadian	LOADABLE POROUS STRUCTURES FOR USE AS IMPLANTS	3.105,045 06-25-2019		PCT/US2019/039 070 06-25-2019	PCT National Phase	Rajesh A. Patel	Titan Pharmaceutic als, Inc.	Filed
43									
30414-20047.	EP European	LOADABLE POROUS STRUCTURES FOR USE AS IMPLANTS	19825459.1 06-25-2019		PCT/US2019/039 070 06-25-2019	PCT National Phase	Rajesh A. Patel	Titan Pharmaceutic als, Inc.	Filed
44									
30414-20047.	IN Indian	LOADABLE POROUS STRUCTURES FOR USE AS IMPLANTS	202017055642 06-25-2019		PCT/US2019/039 070 06-25-2019	PCT National Phase	Rajesh A. Patel	Titan Pharmaceutic als, Inc.	Filed
45									
30414-20047.	JP Japanese	LOADABLE POROUS STRUCTURES FOR USE AS	2020-572459 06-25-2019		PCT/US2019/039 070 06-25-2019	PCT National Phase	Rajesh A. Patel	Titan Pharmaceutic als, Inc.	Filed
46									

		IMPLANTS							
30414-20047.47	MX Mexican	LOADABLE POROUS STRUCTURES FOR USE AS IMPLANTS	MX/a/2020/014159 06-25-2019	PCT/US2019/039070 06-25-2019	PCT National Phase	Rajesh A. Patel	Titan Pharmaceuticals, Inc.	Filed	
30414-20047.48	HK Hong Kong	LOADABLE POROUS STRUCTURES FOR USE AS IMPLANTS	62021041050.7 06-25-2019	19825459.1 06-25-2019	Re-registratio n of European Patent Applicatio n	Rajesh A. Patel	Titan Pharmaceuticals, Inc.	Filed	
30414-20048.00	US United States	IMPLANTS FOR RELEASE OF LIPOPHILIC OR AMPHIPHILIC PHARMACEUTICAL SUBSTANCES	17/253,078 06-25-2019	PCT/US2019/039072 06-25-2019	PCT National Phase	Rajesh A. Patel Sunil Sreedharan Benjamin Furman	Titan Pharmaceuticals, Inc.	Filed	
30414-20048.41	AU Australian	IMPLANTS FOR RELEASE OF LIPOPHILIC OR AMPHIPHILIC PHARMACEUTICAL	2019294615 06-25-2019	PCT/US2019/039072 06-25-2019	PCT National Phase	Rajesh A. Patel Sunil Sreedharan Benjamin	Titan Pharmaceuticals, Inc.	Filed	



		SUBSTANCES					Furman		
30414-20048.	CN Chinese	IMPLANTS FOR RELEASE OF LIPOPHILIC OR AMPHIPHILIC PHARMACEUTICAL SUBSTANCES	201980055348. 1		PCT/US2019/039 072 06-25-2019	PCT National Phase	Rajesh A. Patel Sunil Sreedhar an Benjamin Furman	Titan Pharmaceutic als, Inc.	Filed
30414-20048.	CA Canadian	IMPLANTS FOR RELEASE OF LIPOPHILIC OR AMPHIPHILIC PHARMACEUTICAL SUBSTANCES	3,104,513 06-25-2019		PCT/US2019/039 072 06-25-2019	PCT National Phase	Rajesh A. Patel Sunil Sreedhar an Benjamin Furman	Titan Pharmaceutic als, Inc.	Filed
30414-20048.	EP European	IMPLANTS FOR RELEASE OF LIPOPHILIC OR AMPHIPHILIC PHARMACEUTICAL SUBSTANCES	19827051.4 06-25-2019		PCT/US2019/039 072 06-25-2019	PCT National Phase	Rajesh A. Patel Sunil Sreedhar an Benjamin Furman	Titan Pharmaceutic als, Inc.	Filed
30414-20048.	IN Indian	IMPLANTS FOR RELEASE OF LIPOPHILIC OR AMPHIPHILIC PHARMACEUTICAL SUBSTANCES	202017055647 06-25-2019		PCT/US2019/039 072 06-25-2019	PCT National Phase	Rajesh A. Patel Sunil Sreedhar an	Titan Pharmaceutic als, Inc.	Filed

		CAL SUBSTANCES				Benjamin Furman		
30414- 20048. 46	JP Japanese	IMPLANTS FOR RELEASE OF LIPOPHILIC OR AMPHIPHILIC PHARMACEUTI CAL SUBSTANCES	2020-572496 06-25-2019	PCT/US2019/039 072 06-25-2019	PCT National Phase	Rajesh A. Patel Sunil Sreedhar an Benjamin Furman	Titan Pharmaceutic als, Inc.	Filed
30414- 20048. 47	MX Mexican	IMPLANTS FOR RELEASE OF LIPOPHILIC OR AMPHIPHILIC PHARMACEUTI CAL SUBSTANCES	MX/a/2020/014 160 06-25-2019	PCT/US2019/039 072 06-25-2019	PCT National Phase	Rajesh A. Patel Sunil Sreedhar an Benjamin Furman	Titan Pharmaceutic als, Inc.	Filed
30414- 20048. 48	HK Hong Kong	IMPLANTS FOR RELEASE OF LIPOPHILIC OR AMPHIPHILIC PHARMACEUTI CAL SUBSTANCES	62021041048.1 06-25-2019	19827051.4 06-25-2019	Re- registratio n of European Patent Applicatio n	Rajesh A. Patel Sunil Sreedhar an Benjamin Furman	Titan Pharmaceutic als, Inc.	Filed

TRADEMARK  
REEL: 008196 FRAME: 0280

**SCHEDULE 2  
ASSIGNED TRADEMARK REGISTRATIONS AND APPLICATIONS**

Case Ref	Title	Official No	Country	Main Status	Case Status	Next Due Date	Client Owner
30414-6007.001	PROBUPHINE	4,102,980	US	Registered	Registered	Renewal Due: 02/21/2032	Titan Pharmaceuticals, Inc.
						2/21/2012	Titan Pharmaceuticals, Inc.
30414-6007.107	PROBUPHINE	TMA1012616	CA	Registered	Registered	Renewal Due: 01/10/2034	Titan Pharmaceuticals, Inc.
						1/10/2019	Titan Pharmaceuticals, Inc.
30414-6016.003	PRONEURA	5,492,404	US	Registered	Registered	Sections 8 and 15 Due: 06/12/2024	Titan Pharmaceuticals, Inc.
						6/12/2018	Titan Pharmaceuticals, Inc.

30414-6016.102	PRONEURA	4821226	JP	Registered	Registered	Renewal Due: 11/26/2024	Titan Pharmaceuticals, Inc.
							Titan Pharmaceuticals, Inc.

30414-6016.103	PRONEURA	524391	CH	Registered	Registered	Renewal Due: 06/01/2024	Titan Pharmaceuticals, Inc.
		8/17/2004					Titan Pharmaceuticals, Inc.

30414-6016.104	PRONEURA	004940359	EM	Registered	Registered	Renewal Due: 03/01/2026	Titan Pharmaceuticals, Inc.
		3/1/2006					Titan Pharmaceuticals, Inc.

30414-6016.105	PRONEURA	TMA1038832	CA	Registered	Registered	Renewal Due: 07/09/2029	Titan Pharmaceuticals, Inc.
							Titan Pharmaceuticals, Inc.

**Web Domains:**

oudimplantaccessprogram.com

probuphine.com

probuphineaccess.com

probuphineaccessprogram.com

probuphinerems.com

**TRADEMARK**  
**REEL: 008196 FRAME: 0284**

